An update on pharmacological prospectives for prevention and development of cataract

Indian Journal of Pharmacology

Volumn 29, Issue 1, 1997, Pages 3-10

  Gupta, S K ^a   Joshi, Sujata ^a   Velpandian, T ^a   Awor, Len ^a   Prakash, J ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

antioxidants; free radicals; glutathione; NSAIDs; vitamins

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ALRESTATIN; AMINO ACID DERIVATIVE; ANTIOXIDANT; ASCORBIC ACID; BENDAZAC; BENZYL ALCOHOL; BETA CAROTENE; BIOFLAVONOID; CATALIN; CINERARIA; GERMANIUM DERIVATIVE; GLUTATHIONE; HERBACEOUS AGENT; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PANTETHINE; PARACETAMOL; PHAKEN; PONALRESTAT; SORBINIL; SULINDAC; THIOCTIC ACID; TOLRESTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; VITAMIN B GROUP;

ANIMAL MODEL; BLINDNESS; CATARACT; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG EFFICACY; HUMAN; NONHUMAN; RASH; REVIEW; VISUAL DISORDER;

EID: 0031052734     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Sasaki K, Karinok, Kojima M et al Cataract survey in the local area using photographic documentation. Dev Ophthalmol 1987;15:28-36.
2. Faal H, Minassian D, Sowa S, Foster A. National survey of blindness and low vision in the Gambea: Results. Br J Ophthalmol 1989;73:82-7.
3. Minassian DC, Mehra V. 3.8 million blinded by cataract each year. projections from the first epidemioiogical study of incidence of cataract blindness in India. Br J Ophthalmol 1990;74:341-3.
4. Harding J. Cataract: Biochemistry, epidemiology and Pharmacology London: Chapman - Hall, 1991:83-124.
5. Clark JI. Development and maintenance of lens transparency. In: Albers EM, Jakobiec FA (eds). Principles and Practice of Ophthalmology. Philadelphia: W.B. Saunders, 1994b: 114-23.
6. Miesbauer LR, Zhou X, Yang Z et al. Post translational modifications of water soluble human lens crystallins from young adults. J Biol Chem 1994;269:12494-502.
7. Kador PF, Kinoshita JH. Diabetic and galactosaemic cataracts. Ciba Fdn Symp 1984;6:110-31.
8. Crabbe MJC. Aldose reductase inhibitor and cataract. Intemational Ophthalmol 1991,15;25-36
9. Stribling D. Clinical trials with aldose reductase inhibitors. Exp Eye Res 1990;50:621-4.
10. Stribling D, Mirrleas DJ, Harrison HE, Earl DCN properties of ICI 128436, a novel aldose reductase inhibitor, and its effect on diabetic complications in rat. Metabolism 1985;34:336-44.
11. Sharma YR, Cotlier E. Inhibition of lens and cataract aldose reductase by protein bound antirheumatic drugs, salicylate, indomethacin, oxyphenbutazone, sulindac. Exp Eye Res 1982;35:21-7.
12. Lerman S, Moran M. Sorbitol generation and its inhibition by sorbinil in the aging normal human and rabbit lens and human diabetic cataracts. Ophthalmic Res 1988;20: 348-52.
13. Harding JJ. Pharmacological Treatment Strategies in age related cataracts. Drugs Aging 1992;2:287-300.
14. Mohan M, Gupta SK. Agnihotri S, Joshi S, Uppal RK. Anticataract action of topical quercetin and myricetin in galactosemic rats. Med Sci Res (U.K) 1988;16:685-6.
15. Datiles M, Fukui H, Kuwabara T, Kinoshita JH. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor a light microscopic study. Invest Ophthalmol Vis Sci 1982;22:174-9.
16. Srivastava SK, Ansari NH, Hair GA, Jaspan J, Rao M. Hyperglycaemia-induced activaton of human erythrocyte aldose reductase and alterations in kinetic properties. Biochemica Biophysica Acta 1986;870:302-11.
17. Nagaraj RH, Monnier VM Non-tryptophan fluorescence and high molecular weight protein formation in lens crystallins of rats with chronic galactosemia; Prevention by aldose reductase inhibitor. Sorbinil Exp Eye Res 1990; 51:411-8.
18. Wolff S, Crabbe MJC. Low apparent aldose reductase activity produced by monosaccharide autooxidation. Biochemical J 1985;226:625-30.
19. Gamer MH, Wang G, Spector A. Stimulation of glycosylated lens epithelial Na,- K,- ATPase by an aldose reductase inhibitor. Exp Eye Res 1987,45:339-45.
20. Cotlier E, Sharma YR. Aspirin and senile cataracts in rheumatoid arthritis. Lancet 1981;1:338-9.
21. Harding JJ, Egerton M, Harding RS. Protection against cataract by aspirin, paracetamol and ibuprofen. Acta Ophthalmol 1989b;67;518-24.
22. Gupta SK, Joshi S. Relationship between aldose reductase inhibiting activity and anti-cataract action of various NSAIOs. Dev Ophthalmol 1991;21:151-6.
23. Bono A, Militello A, Bongiomo A et al. Effects of bendazac L-lysine salt on some metabolic enzymes of glutathione in the rabbit lens after x-ray irradiation. Italian J Biochem 1987;36:153-65.
24. Harding JJ, Rixon KC. Carbamylation of lens proteins: a possible factor in cataractogenesis in some tropical countries. Exp Eye Res 1980;31:567-71.
25. Woollard ACS, Wolff SP, Bascal ZA. Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol and bendazac provide support for an oxidative component of cataract. Free Rad Biol Med 1990;9:299-305.
26. Gupta SK, Joshi S. Naproxen. An aldose reductase inhibitor and potential anti-cataract agent. Dev Ophthalmol 1991;21:171-8.
27. Gupta SK, Joshi S. Role of Naproxen as antioxidant in selenite cataract. Ophthalmic Res 1994;26:226-31.
28. Gupta SK, Joshi S. Prevention of photoperoxidation of lens lipids by naproxen. Afro Asian J Ophthalmol 1993;12:295-7.
29. Gupta SK, Agnihotri S, Joshi S. Anti-cataract action of topical sulindac (IH-indene-3-acetic acid, 5 fluoro 2 methyl methylene) in galactosemic rats. Afro-Asian J Ophthalmol 1989;8:57-61.
30. Cammarata PR, Jackson T, Yorio T. Sorbinil prevents the galactose induced inhibition of prostaglandin synthesis in lens cells. Invest Ophthalmol Vis Sci 1988;29:1452-60.
31. Harding JJ, van Heyningen R. Case control study of cataract in Oxford. Dev Ophthalmol 1987;15:99-103.
32. Eckerskom V, Hockwin O, Muller-SreitenKamp R, Chen TT, Knowles W. Evaluation of cataract related nsk factors using detailed classification systems and multivariate statistical methods. Dev Ophthalmol 1987;15.82-91.
33. Mohan M, Sperduto RO, Surender KA. Milton RC, Mathur RL et al. US case control study of age related cataract. Arch Ophthalmol 1989;107:670-6.
34. Balfour JA, Clissold SP. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs 1990;39:575-96.
35. Silvestrini B. Rationale for bendazac. In: D' Ermo et al (eds) Recent developments in the pharmacological treatment of cataract. Amsterdam: Kugler, 1987:1-9.
36. Levis BS, Harding JJ. The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis. Exp Eye Res 1988;47:217-25.
37. Pandolfo L, Livrea MA, Bono A. Effects of bendazac L. lysine salt on x-ray induced cataract in the rabbit lens. Exp Eye Res 1986;42:167-75.
38. Testa M, Iuliano G, Silvestrini B. Pilot study of bendazac for treatment of cataract. Lancet 1982;1:849-50.
39. Harding JJ Free and protein-bound glutathione in normal and cataractous human lenses. Biochem J 1970;117:957-60.
40. Highfower KR. Superficial membrane-SH groups inaccessible by intracellular GSH. Current Eye Res 1986;5:421-7.
41. Ajiboye R, Harding JJ. The non-enzymatic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione. Exp Eye Res 1989;49:31-41.
42. Ross WM, Creighton MO, Trevithick JR. Modelling cortical cataractogenesis: VI. Induction by glucose in vitro or in diabetic rats: prevention and reversal by glutathione. Exp Eye Res 1983;37:559-73.
43. Hockwirt O, Weigelin E, Baur M, Boutros G. Kontrollierte Klinische studie uber die wirksankeit von Phakan als Antikataractmedicament. Fortschritte der Ophthalmologie 1982,79:179-83.
44. Raj DG, Ram Krishnan S, Devi SS. Myonisitol and peroxidation an in vitro study on human cataractous lens and human erythrocytes. Ind J Biochem Biophys 1995;32: 109-11.
45. Ram Krishna S, Sulochana KN. Decrease in glycation of lens proteins in lysine and glycine by scavenging of glucose and possible mitigation of cataractogenesis. Exp Eye Res 1993;57:623-8.
46. Ramakrishnan S, Sulochana KN, Punnitham R, Badrinath SS. Inositol as an antiglycating substance. A new function in the tens. Invest Ophthalmol and Vis Sci 1995;36: S883.
47. Prchal JT, Conrad HW, Shalka HW. Association of presenile cataracts with heterozygosity for galactosemic state and with riboflavin deficiency. Lancet 1978;1:12-3.
48. Booth AA, Khalifah RG, Hudson BG. thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end. products: Comparison with aminoguanidine: Biochem Biophys. Res Conmun 1996; 220:113-9.
49. Hyslop PA, Hinshaw DB, Halsey WA Jr. et al. Mechanism of oxidant mediated cell injury: the glycolytes and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J Biol Chem 1988;263:1665.
50. Bunce GE, Kinoshita JH, Horwitz J. Nutritional factors in cataract. Ann Review Nutr 1990;10:233-54.
51. Greighton MO, Ross WM, Stewart. De Haan PJ, Sanwal M, Trevithick JR. Modelling cortical cataractogenesis VII. Effects of vitamin treatment on galactose induced cataracts. Exp Eye Res 1985;40:213-22.
52. Mansour SA, Richards RD, Kuck JF, Varma SD. Effect of artioxidant (vitamin E) on the progress of cataracts in Emory mice. Invest Ophthalmol Vis Sci 1984;25: 38(abstr).
53. Linkater MA, Dzialoszynaski T, Mcleod HL, Sanfood SE, Trevithick JR. Modelling cortical cataractogenesis XI. Vitamin C reduces crystalline leakage from lenses in diabetic rats. Exp Eye Res 1990;51:241-7.
54. Varma SD. Scientific basis for medical therapy of cataracts by antioxidants. Am J Clin Nutr 1991;53:335-455.
55. Varma SD, Morris SM, Baur SA, Koppenol WH. In vitro damage to rat lens by xanthine-xanthine oxidase: protection by ascorbate. Exp Eye Res 1986;43:1067-76.
56. Varma SD, Kumar S, Richards RD. Light induced damage to ocular lens cation pump: prevention by vitamin C. Proc Nutr Acad Sci USA 1979;76:3504-6.
57. Varma SD, Srivastava VK, Richards RD. Photoperoxidation in lens and cataract formation: preventive role of superoxide, catalase and vit C. Ophthalmol Res 1982;4:167-75.
58. Jacques PF, Hartz SC, Chylack LT, Mc Gandy RB, Sadocoski JA. Nutritional status in persons with and without senile cataract blood vitamin and mineral levels. Am J Clin Nutr 1988;48:152-8.
59. Varma SD, Richards RD, Morris SM. Ocular damage by hematoporphyrin and light. In vitro studies with lens. Lens Res 1986;3:319-33.
60. Zigler JS, Goosey JD. Singlet oxygen as a possible factor in human senile cataract development. Curr Eye Res 1984;3:59-65.
61. Robertson JM, Donner AP, Trivithick JR. Vitamin E intake and risk of cataract in humans. Ann N Y Acad Sci 1989; 570:372-82.
62. Kuck JFR. Cataract formation. In. Greymore CN (ed), Biochemistry of the eye. New York: Academic Press Inc, 1970: 319-71.
63. John A, Bhat KS. Effect of riboflavin deficiency on low tryptophan induced cataract in male rats. Nutr Res 1992; 12:1373-81.
64. Bunce GE, Kinoshita JH, Horwitz J. Nutritional factors in cataract Ann Rev Nutr 1990;10:233-54.
65. Balasubramaniyan D, Bhat KS, Rao GN. Factors in the prevalence of cataract in India: Analysis of the recent Indian-US study of age related cataracts. Curr Sci 1990;59:498-505.
66. Bhat KS. Nutrition and cataract. Bulletin Nutr Fond India 1993;14:1-3.
67. Bhat KS, Gopalan C. Human cataract and galactose metabolism. Nutr Metabol 1974;17:1-8.
68. Vani RR, Rawal UM. Glutathione and glutathione redox cycle in Riboflavin supplemented cataractous rat lenses. Ind J Pharmacol 1996;28:93-7.
69. Sperduto RD, HU TS, Milton BG et al. The Unxian cataract studies: two nutrition intervention trials. Arch Ophthalmol 1993;111:1246-53.
70. Nath B, Srivastava SK, Singh K. Accumulation of copper and inhibition of lactate dehydrogenase activity in human senile cataractous lens Ind J Biol 1969;7:25-6.
71. Bhat KS. Nutritional status of thiamine. riboflavin and pyridoxine in cataract patients. Nutr Rep Int 1987;36:685-92.
72. Shearer TR, David LL, Anderson RA. Selenite cataract a review. Curr Eye Res 1987;6:289-300.
73. Varma SD, Chand D, Sharma YR, Kuck JF, Richards RD. Oxidative stress on lens and cataract formation: role of light and oxygen. Curr Eye Res 1984;3:35-57.
74. Varma SD, Devamanoharan PS, Morris SM. Photoinduction of cataracts in rat lens in vitro. Preventive effect of pyruvate. Exp Eye Res 1990;50:805-12.
75. Unakar KJ, Johnson M, Tsui J, Cherian M, Abraham E. Effect of Germanium - 132 on galactose cataract and glycation in rats. Exp Eye Res 1995;61:155-64.
76. Stevens A. The effectiveness of putatuve anticataract agents in the prevention of protein glycation. J Am Optomassoc 1995;66:744-9.
77. Maitra I, Serbinova E, Trischier H, Packer L. Alpha-lipoic acid prevents buthionine sulfoximine induced cataract formation in newborn rats. Free Rad Biol Med 1995;18: 823-9.
78. Hiraoka T, Clark JI, Lixy, Thurston GM. Effect of selected anticataract agents of opacification in the selenite cataract model. Exp Eye Res 1996;62.11-9.
79. Kobayashi S, Kasuya M, Shimizu K, Takehana M, Sakai K, Suzuki N, Itoi M. Glutathione isopropyl ester (YM 737) inhibits the progression of x-ray induced cataract in rats. Curr Eye Res 1993;12:115-22.
80. Kuck JF Jr., Kuck KD. The Emory mouse cataract: The effects of cataractogenesis of alpha-tocopherol, penicillamine, triethylenetetramine and mercapto- propionylglycine. J Ocular Pharmacol 1988;4:243-51.
81. Wang Z, Hess JL, Bunce GE: Deferoxamine effect on selenite induced cataract formation in rats. Invest Ophthalmol Vis Sci 1992;33:2511-9
82. Angra SK, Mohan M, Saini JS. Medical therapy of cataract (Evaluation of Catalin). Ind J Ophthalmol 1983;31:5-8.
83. Albel MV, Chandorkar AG, Bulakia PM. Evaluation of catalin, Success cineraria Maritima and catobell in goat lens cultures. Ind J Ophthalmol 1981;29:147-9.
84. Sharma P, Gupta SK, Madan Mohan, Arya AV. Benzyl alcohol a topical anti-cataract agent Afro-Asian J Ophthalmol 1990;19:50-3.